About Us

Optolytics had its origin in 1992 when we began to study portable devices to measure psychometric values to assess the degree of cognitive stimulation or sedation from medication.  Research involved measuring critical flicker fusion in Parkinson’s Disease and patients using narcotic medication. Today, Optolytics’ goal is to develop a mobile device application to quickly assess concussions in athletes on the field. 

Leadership

Richard L. Peatman, Pharm.D., brings over three decades of healthcare experience to his role. He did his undergraduate work at U.C.L.A. and received a Doctor of Pharmacy degree from U.S.C.  His career spans clinical work with the Dept. of Cardiothoracic Surgery at U.C.L.A., Methodist Hospital of Sacramento, and private pharmacy practice.  He is passionate about developing practical diagnostic devices that can be inexpensively and conveniently used by coaches, trainers, and medical personnel immediately after a potential injury.